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Abstract

Long-term contraceptives are a needed measure for
prevention of unintended pregnancies. Depot
medroxyprogesterone acetate

(Depo-Provera), a long-term

injectable contraceptive, is particularly useful for
adolescent women. Despite the widespread use of DepoProvera,

limited data exist in the literature on

continuation rates, especially among adolescents. The
purpose of this descriptive study was to determine the
factors which influence the choice and discontinuation of
D epo-Provera among adolescents. The Health Belief Model
served as the theoretical framework to guide this study.
The convenience sample consisted of adolescent females

(N

= 14) . The instrument utilized for the collection of data
was the McCarter Depo-Provera Questionnaire. Responses to
the instrument were analyzed using frequency distributions
and percentages. The majority of the adolescents

(93%)

in

this study were satisfied with Depo-Provera. Most of the
subjects

(86%) chose Depo-Provera because they only had to

remember to get an injection every 3 months. Only 2
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subjects discontinued use of Depo-Provera and attributed
discontinuation to physical and menstrual symptoms.
Conclusions derived from the findings of this study were
that the majority of the adolescents had used another
method of birth control, almost half of the adolescents
had been pregnant, and most of the adolescents had used
Dep o -Provera for 12 months or longer. Recommendations for
future research are replication of the study with a
larger, more diverse sample, replication of the study
without parental consent for participation in the study if
not required for administration of Depo-Provera, and
conduction of research to include past sexual history and
educational level.
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Chapter I
The Research Problem

The United States has the highest rate of adolescent
pregnancy among industrialized countries

(Spitz et al.,

1996). Adolescent pregnancy is a national dilemma that
transcends the boundaries of socioeconomic class, race,
and ethnicity. Adolescent motherhood has negative
consequences for mother and child ("Teen Pregnancy,"
1997). Nearly 60% of all pregnancies in the United States
are unintended and almost one half of these occurred
because contraception failed or was not used properly
(Marble,

1996). Long-term contraceptives are a needed

measure for prevention of unintended pregnancies. Access
to effective long-term contraception should be available
to every woman for prevention of unintended pregnancy,
particularly the adolescent. This study will explore why
adolescents choose and discontinue long-term contraception
with depot medroxyprogesterone acetate

(Depo-Provera).

Establishment of the Problem
Young girls who become pregnant are more likely to be
poor and have limited future possibilities because 70% of
teenage mothers drop out of high school

("Teen Pregnancy,"

1997). These adolescents are more likely to have more
children,

spend more time as a single parent, and rely

more heavily on public assistance than those teens who do
not have children. Pregnant teens are more likely to have
medical problems during their pregnancy and are less
likely to seek prenatal care. The children born to teenage
mothers face many obstacles. Studies have shown that these
children are likely to do worse in school, have
poorer health yet receive less health care, are more
likely to be incarcerated, and have higher rates of
adolescent childbearing themselves

("Teen Pregnancy,"

1997).
Although there are a number of contraceptive options
available to adolescents, many adolescents may be
uninformed about contraceptive choices despite receiving
sex education in school. Studies have shown that 50% of
teenage pregnancies occur within 6 months of first sexual
intercourse and 20% of pregnancies occur within the first
month

(Moriarty,

1997). Some of the available
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contraceptive methods include condoms, spermicides, oral
contraceptive pills, Depo-Provera injections, and the
Norplant system.
Depo-Provera is an injectable contraceptive which was
approved for use in the United States in late 1992. It has
been used worldwide for more than 20 years. This hormonal
injection provides contraceptive protection for up to 3
months. The contraceptive efficacy of Depo-Provera has
been well established with an expected failure rate of
only 0.3%

(Moriarty,

1997). Depo-Provera is a reasonably

affordable method at a cost of approximately $3 0 to $4 0
per injection. Depo-Provera is a particularly useful
method for adolescent women who are typically inconsistent
users of coital-dependent methods or methods which require
daily use. Often adolescents who are sexually active and
started on Depo-Provera fail to return at the required 3month intervals for continued protection from unwanted
pregnancies. Little has been documented about the reasons
for adolescents'

choice of Depo-Provera as a contraceptive

and the factors which account for discontinuation of DepoProvera. The purpose of this study was to determine the
factors which influence adolescents'

choice of Depo-

Provera and discontinuation of Depo-Provera among
adolescents.
After reviewing a number of research studies about
Dep o -Provera, Kaunitz

(1994) concluded that contraception

with Depo-Provera may be ideal for women seeking highly
effective birth control but who experience problems with
other reversible methods.

In reviewing the literature

Kaunitz found that some women selected Depo-Provera
because they had

(a) difficulty remembering to take oral

contraceptive pills daily,

(b) experienced compliance

problems with barrier methods,

(c) preferred the

convenience of one injection every 3 months,

(d) developed

estrogen-related side effects when taking oral
contraceptives, or (e) required the privacy associated
with Depo-Provera use--no one other than the administering
health care provider knew that the drug was being used.
Other women chose Depo-Provera because medical factors
precluded the use of estrogen-containing oral
contraceptive agents or because use of concomitant
medications could possibly reduce the efficacy of oral or
implantable contraception. The third group of women,

for

whom pregnancy posed unacceptable fetal or maternal risks,
selected Depo-Provera because of its extremely high
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contraceptive efficacy. Kaunitz

(1994) recommended patient

education and counseling to minimize Depo-Provera use in
inappropriate candidates,

such as women not willing to

tolerate menstrual changes, women who may wish to conceive
in the next 1 to 2 years, and those unable or unwilling to
return every 3 months for repeat injections.
Pinkston-Koenig and Miller

(1995) conducted a study

that sought to determine the prevalence of, indications
for, and problems associated with the use of Depo-Provera
in adolescents. They found that less than half of the
physicians who responded to questionnaires

(N = 616)

offered Depo-Provera as a contraceptive option to
adolescents.
Problems related to irregular bleeding were involved
with discontinuation. Little is known about the use of and
problems with the use of Depo-Provera in adolescents.
Future investigations into short-term potential problems,
such as weight gain or mood changes, and long-term
potential problems,

such as osteoporosis, were cited as

areas for future studies by Pinkston-Koenig and Miller.
Harel, Biro, Kollar, and Rauh

(1996) concluded that

discontinuation of Depo-Provera and Norplant among
adolescents was largely the result of irregular menstrual
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bleeding and weight gain. Counseling about potential side
effects should be provided before initiation of these
methods and throughout the use of these methods to help
increase continuation.

Significance to Nursing
Because adolescent pregnancy is a national problem
and has negative consequences for both the adolescent
mother and her child, reliable methods of contraception
should be available. Although there are many contraceptive
choices available to adolescents, many adolescents are
often uninformed about contraceptive choices.
Depo-Provera is a very efficacious and cost-effective
method of birth control. It is particularly useful for
adolescent women who are typically inconsistent users of
coital-dependent methods or those which require daily use.
Yet often,

adolescents who are started on Depo-Provera

fail to return at the required 3 -month intervals for
continued protection from unwanted pregnancies.
Information on appointment compliance can alert the health
care provider to focus on ways to improve follow-up
appointments. Little has been documented about the reasons
for adolescents'

choice of Depo-Provera as a contraceptive

and the factors which account for their discontinuation
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with Depo-Provera. Once the factors which account for
discontinuation with Depo-Provera are discovered, measures
can be taken to increase continuation with this method.
Harel et al.

(1996) suggested that counseling about

potential side effects be provided before initiation of
D e p o -Provera and throughout the use of this drug to help
increase continuation with this method. By discovering the
factors that influence adolescents' discontinuation with
Dep o -Provera, health care providers can counsel them on
the potential for these factors and possibly increase
continuation with this method. By anticipating,
counseling,

and attempting to prevent physical problems

associated with the use of Depo-Provera,

the health care

provider may be able to increase adolescents'

continuation

with this method. The health care provider should also
make an effort to increase the use of a barrier method in
adolescents to prevent sexually transmitted diseases. When
discontinuation is requested, the health care provider
should expedite the use of a new contraceptive method in
an attempt to reduce the high pregnancy rate observed
among adolescents after discontinuation of Depo-Provera.

Theoretical Framework
The Health Belief Model will provide the theoretical
framework for this study because sociopsychological
variables are used in the explanation of preventive health
behavior. An individual's motivation to act is considered
a function of the expectancy of goal attainment in the
area of health behavior. The Health Belief Model is
concerned with the subjective world of the acting
individual. The assumptions of this theory are as follows :
. . . in order for an individual to take action
to avoid a disease, he would need to believe
that he was personally susceptible to the
disease, that the occurrence of the disease
would at least have moderate severity on some
component of his life, and that taking a
particular action would in fact be beneficial by
reducing his susceptibility to the condition or,
if the disease occurred, by reducing its
severity, and that it would not entail
overcoming important psychological barriers such
as cost, convenience, pain, and embarrassment.
(Becker, 19974, p. 3)
The Health Belief Model has been shown by current
research to be a value expectancy approach to explaining
and predicting health behaviors that go beyond straight
information giving. This approach can be used to intervene
in encouraging contraceptive use among teenagers. Because
contraceptive action involves a preventive health decision
followed by correct and consistent use, the model may have
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useful applications to both the prevention and compliance
aspects of contraceptive behavior

(Zellman, 1984) .

Individual perceptions of adolescents related to their
perceived susceptibility to pregnancy are important.
Modifying factors include the adolescents' knowledge about
pregnancy prevention, the types of contraceptives,

the

availability of contraceptives, and the consequences of
pregnancy. The likelihood of action includes the
adolescents' perceived benefits of a long-acting
contraception as well as perceived side effects with the
use of this type of contraceptive.

Assumptions
The following assumptions were made for this study :
1. Participants will respond honestly to all items on
the McCarter Depo-Provera Questionnaire.
2. Adolescents use contraception to prevent
pregnancies.
3. Adolescents' actions to discontinue Depo-Provera
as a contraception is based on a perceived benefit/side
effect evaluation.
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Purpose of Jthe Study
The purpose of this study was to determine the
factors which influence the choice of and discontinuation
of Depo-Provera among adolescents.

Statement of the Problem
According to Spitz et al.

(1996), pregnancy and birth

rates among teenage girls in the United States are the
highest of any developing country. There were 95.9
pregnancies per 1,000 teenage girls between the ages of 15
and 19 years by 1990 which reflected a 9% increase over
the last half of the decade

(Spitz et al.,

1996). A number

of contraceptive options are available to adolescents.
Some of the available methods include condoms,
spermicides, oral contraceptive pills, Depo-Provera
injections,

and the Norplant system. Depo-Provera has been

introduced as a means for long-term contraception. Yet
adolescents who are sexually active and started on DepoProvera often fail to return at the required 3 -month
intervals for continued protection from unwanted
pregnancies. Little has been documented about the reasons
for adolescents'

choice of contraceptives and the factors

which account for their discontinuation with Depo-Provera.
The purpose of this study was to determine the factors
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which influence choice of and discontinuation of DepoProvera among adolescents.

Research Questions
The two research questions answered as a result of
this study were as follows :
1. What are the factors identified by adolescents
that influence the choice of Depo-Provera as a
contraceptive method?
2. What are the factors identified by adolescents
that influence discontinuation of Depo-Provera as a
contraceptive method?

Definition of Terms
For the purpose of this study, the following terms
were defined :
Factors : the perceived reasons for choosing DepoProvera as a contraceptive and for discontinuation of
D e p o -Provera as identified on the McCarter Depo-Provera
Questionnaire.
Choice of Depo-Provera: decision by females between
the ages of 13 and 2 0 years to use Depo Provera as a
contraceptive method.
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Discontinuation of Depo-Provera: failure to return on
the prescribed date for intramuscular injection of DepoProvera.
Adolescents : females between the ages of 13 and 2 0
years who seek contraception with Depo-Provera.

Chapter II
Review of the Literature

A review of the literature revealed some information
about the reasons adolescents choose and discontinue DepoProvera. Many of the adolescents who chose Depo-Provera
did so because of ease of use, cost, privacy,

and

dissatisfaction with oral contraceptive pills. The
literature indicated that the majority of adolescents who
discontinue Depo-Provera do so because of perceived
adverse side effects. Some of the adverse side effects
cited in the review of the literature included weight
gain,

irregular menstrual cycles, headaches, and mood

swings.
Cromer,

Smith, Blair, Dwyer, and Brown

(1994)

conducted a prospective study to examine adolescents'
contraceptive choices between long-term contraceptives,
either 1evonorge s tre1 implant
medroxyprogesterone acetate
oral contraceptive pill

(Norplant) or

(Depo-Provera), and a combined

(OCP). The researchers established

a baseline of physical signs and symptoms present before
13
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use of the chosen contraceptive form in order to compare
these variables among the different groups on a
longitudinal basis. Cromer et al.

(1994) also

measured perceived satisfaction and continuation rates
among the users of the different forms of
contracept i o n .
The subjects of this study (N = 199) were adolescent
females between the ages of 11 and 2 0 years who desired
contraception. Each subject selected a contraceptive
method of choice, with 38% selecting OCP, 33% selecting
Depo-Provera, and 29% selecting Norplant. The subject
groups ranged in age from 15.2 to 15.7 years.
Socioeconomic status was generally low, with Hoi1ingshead
scores ranging from 23 + 11 to 26 + 14.5. Of the three
study groups,

63% to 67% were African-American; the

remaining participants were Caucasian. Of the 199
participants,

27% had been pregnant previously,

teen parents,

and 9% previously had abortions. Of those

who had pregnancy histories,

24% were

68% reported prior use of a

birth control method, as compared with 33% of the
remaining girls who had never been pregnant

(x^ = 18.36, p

< .01). Data were obtained initially and on follow-up
visits at 3 months and 6 months after entering into the
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study and beginning a regime on the chosen form of
contraception. Cromer et al.

(1994) obtained data through

an interview and physical examination.
The baseline of physical signs and symptoms was
established before beginning the study in order to
accurately determine the signs and symptoms caused by the
use of one of the three contraceptive forms. Gynecological
symptoms surveyed before beginning the study were dysuria,
vaginal discharge, vaginal itch, pelvic pain, and
menstrual history. The prevalence of sexually transmitted
diseases

(STDs) was also evaluated.

Medical symptoms which have been associated with
progestin or estrogen therapy were also reviewed to
establish a baseline. These symptoms included depression,
fatigue, headache, dizziness,

and nausea. Physical

examination characteristics recorded were mean blood
pressure,
method,

facial acne, previous use of a birth control

and previous reproductive experiences.

The methods of analysis included means and standard
deviations for the descriptive data as well as

analysis

and t tests for inferential comparisons. Changes in
occurrence rates of medical and gynecologic symptoms
before and after initiation of treatment were assessed by
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the use of McNemar's test on data obtained from those
subjects who returned for follow-up.
In the baseline findings of the gynecological
symptoms, Cromer et al.

(1994) found no significant

difference in complaints of dysuria, vaginal discharge,
vaginal itch, pelvic pain, and menstrual history among the
three groups. The prevalence of STDs in the group who
chose Depo-Provera was higher than in those who chose
Norplant or the OCP. No significant differences in the
frequency of complaints of depression,
dizziness,

fatigue, headache,

and nausea were found among the three groups.

There were no significant differences among the three
groups on mean blood pressure or facial acne. The group
who chose Depo-Provera was significantly more likely to
have used some other form of contraception in the past.
Those who chose either Norplant or Depo-Provera were
significantly more likely to have had a reproductive
experience.
At the end of 3 months,

105 adolescents

(Depo-

Provera, n = 38; Norplant, n = 4 0; OCP, n = 2 7) remained
in the study, and at the end of 6 months 4 0 adolescents,
evenly distributed across the three groups, remained in
the study. Over 8 0% of those treated with either Norplant
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or Depo-Provera had experienced irregular menstrual
bleeding. Of those who received Depo-Provera, 34% were
amenorrheic by the end of 3 months, and 60% were
amenorrheic by the end of 6 months. About one third of the
Norplant users were amenorrheic at the end of 3 months
with no increase in this percentage at the end of 6
months.

Irregular bleeding in the Depo-Provera users

decreased by the end of the 6 -month period. Of the
Norplant users,

irregular bleeding occurred in about one

third of the users at the end of 3 months and remained
stable at the end of 6 months. Of the adolescents who used
the OCP, almost 90% experienced regular cycles.
In comparing the gynecologic and medical symptoms,
only those who returned for follow-up assessments provided
data for analysis. Cromer et al.

(1994) found no

significant changes in gynecological symptoms,

such as

vaginal discharge, dysuria, vaginal itch, or pelvic pain,
from the baseline to the follow-up. More of the girls
taking Depo-Provera

(n = 4, 10%) and Norplant

as compared with those taking the OCP

(n = 5, 12%)

(n = 2, 7%) had

occurrences of sexually transmitted diseases at the end of
the 3 -month follow-up.
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Medical symptoms reviewed showed the most common
complaints among the three groups were depression,
headache, and fatigue, which were reported more frequently
among those using Depo-Provera. These results revealed no
increase in the frequency of complaints related to
depression, headache, dizziness, or nausea among the three
groups after initiation of treatment than before
initiation of treatment. Results of the physical
examination characteristics showed no significant
differences among the users of the three forms of
contraceptives at the 3 -month follow-up and at the 6 -month
follow-up.
Compliance with appointments also was calculated
among the three groups. Appointment compliance was defined
as the appearance in the clinic within 2 weeks of a
scheduled appointment without prompting. Compliance with
appointments at the 3 -month follow-up was highest among
the Depo-Provera users

(66%), followed by the OCP users

(51%), and the Norplant users

(49%). At the end of the 6-

month follow-up the Depo-Provera users

(78%) remained the

most compliant group compared with those using Norplant
(40%) or the OCP

(46%)

(%' = 12.23, p < .01).
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Cromer et al.

(1994) found that Norplant and Depo-

Provera are very popular contraceptives for adolescent
females, especially among those who have used other forms
of contraception or have had reproductive experiences. The
researchers stressed the importance of a baseline
evaluation of signs and symptoms is important to have
before initiation of therapy in order to better evaluate
reported signs and symptoms after initiation of therapy.
Users of Norplant are more likely to experience the side
effects of nausea and dizziness, whereas Depo-Provera
users are more likely to experience amenorrhea and
fatigue. Another finding was that interventions are needed
to encourage compliance with follow-up appointments in
those using Norplant and OCP. Cromer et al.

(1994)

recommended that a similar study be conducted on
adolescents who require confidentiality to determine
variables that may impact decision making on those
adolescents without parental guidance.
In another descriptive study conducted by Freda et
al.

(1996), women's responses to Depo-Provera were

assessed. The population consisted largely of Medicaid
recipients served by the inner-city facility. Seventy-two
women who had received the contraceptive in the facility
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were asked a series of questions,
Depo-Provera,

including why they chose

the side effects they experienced,

if they

intended to continue its use, and what they would tell a
friend about Depo-Provera. Freda et al.

(1996) hoped to

better educate other women by learning how women feel
about this birth control option.
Women who had received at least one injection of
Depo-Provera in the facility were contacted and
interviewed by telephone, using a demographic form and a
14-item questionnaire. The following demographic data were
obtained; age, race, education,

insurance, and marital

status. Sixty-three percent of the final sample
were Hispanic,

(n = 72)

29% were black, and 8% were white. The mean

educational level was 11.4 years of completed education.
The mean age was 2 7.7 years. Seventy-seven percent of the
sample were on Medicaid,

13% self-paid, and 10% used

private insurance to pay for their birth control method.
Sixty percent of the sample were unmarried.
The questionnaire contained questions pertaining to
the following information : (a) the three main things the
interviewee would tell another woman about Depo-Provera,
(b) reason for choosing Depo-Provera, (c) satisfaction
with Depo-Provera as a method of birth control,

(d)
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satisfaction with the information received from the
doctors or nurses before the first injection,
condoms since using Depo-Provera,
partners in the past 6 months,

(e) use of

(f) number of sexual

(g) symptoms considered by

the user to be side effects of Depo-Provera, (h) whether
the interviewee planned to have another Depo-Provera
injection,
and

(i) length of time planned to use Depo-Provera,

(j) whether the interviewee planned to become pregnant

again. The respondents in this study were mostly Hispanic
(63%) and unmarried (60%). At the time of the interview,
35% had received only one injection and 33% had received
two injections. Eighteen percent had three, and 14% had
four injections.
Freda et al.

(1996)

found that dissatisfaction with

oral contraceptives was the typical reason given for
choosing Depo-Provera. Ninety-three percent of the women
were satisfied with the information they received before
their first injection. Eighteen percent thought that the
injectable contraceptive prevented STDs, and 56% reported
that they never used condoms since using Depo-Provera.
Of the women interviewed, the majority

(78%)

expressed satisfaction with the method and 64% planned to
continue its use. A scheduled tubal ligation was the most
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common reason provided for termination of Depo-Provera.
Sixty-five percent of the respondents experienced side
effects. Amenorrhea,

followed by headaches, hair loss,

irregular periods, and heavy bleeding were the most
commonly reported side effects of Depo-Provera.
Women offered multiple responses as to why they chose
this method. Twenty-five percent of the women reported
forgetting to take the pills as their reason for choosing
D e p o -Provera, which was the most common reason. Other
typical reported reasons were "dislike of the pills

(20

percent), advice from a doctor or midwife to try DepoProvera
method

(18 percent), the ease and perceived safety of the
(18 percent), and the fact that it is used every

three months

(12 percent)"

(p. 185). Five respondents

reported that they had used Depo-Provera in different
countries and wanted to use it again, and 9 chose to use
it while they were breast-feeding.
Freda et al.

(1996)

found that 78% of the respondents

expressed satisfaction with the method, compared to 22%
who were not satisfied. The following reasons were given
for dissatisfaction : "too much bleeding,"
"pimples on my face,"

"bad headaches,"

"losing my hair," and "gaining
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weight"

(p. 185). Sixty-five percent planned to have

another injection despite the dissatisfaction rate.
When the respondents were asked what they would tell
a friend about Depo-Provera,

the most common answers to

this question were "easy," "safe," "don't have to think
about it for three months,"
getting pregnant,"

"don't have to worry about

"don't get periods all the time," "You

could gain weight," and "You might lose some hair."

"You

can use it while you're breast-feeding" was one woman's
response. Unfortunately,

6% responded that "You don't have

to use condoms" and 18% reported variations of "It
prevents sex diseases"
Freda et al.

(p. 185).

(1996) discovered that side effects were

experienced by 65% of the respondents. The most common
side effects were no periods
loss

(27%), irregular periods

(31%), headaches

(27%), hair

(22%), and heavy bleeding

(19%) . Satisfaction with patient education given before
their first injection was reported by 93% of the women.
Freda et al.

(1996) found that the most common reason

reported for choosing Depo-Provera was forgetting to take
the oral contraceptive pills. Other reasons were dislike
of the pills, the ease and perceived safety of DepoProvera, and the fact that it is needed only every 3
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months. The most common reason provided for termination of
Depo-Provera was a scheduled tubal ligation. More than
half of the respondents experienced side effects,

such as

amenorrhea, headaches, hair loss, irregular periods,

and

heavy bleeding. More than three quarters of the
respondents expressed satisfaction with the method and
planned to continue its use. Unfortunately,

6% responded

that condom use was not needed with Depo-Provera use, and
18% reported that Depo-Provera prevents sexually
transmitted diseases

(Freda et al., 1996).

Pinkston-Koenigs and Miller

(1995) sought to

determine the prevalence of, indications for, and problems
associated with the use of Depo-Provera as a means of
contraception among adolescents in the United States. The
researchers believed that the primary reason adolescent
health care providers hesitated to prescribe Depo-Provera
was because its use as a contraceptive had not yet been
approved by the Food and Drug Administration

(FDA).

The researchers mailed 1,026 questionnaires to
physicians in the United States who were members of the
Society of Adolescent Medicine, the North American Society
of Pediatric and Adolescent Gynecology, and directors of
adolescent medicine fellowship programs, but no physician
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was surveyed more than once. A follow-up mailing yielded a
total response rate of 60%

(N = 616). SYSTAT version 5.1

was used for statistical analysis. The demographic
characteristics of physicians who prescribed Depo-Provera
in their practices were compared using chi-square tests at
a p value of < .05.
Demographic results revealed that "25% of the
respondents were trained in pediatrics alone, 3 9% in both
pediatrics and adolescent medicine, and 14% in obstetrics
and gynecology"

(Pinkston-Koenigs & Miller,

1995, p. 348).

The remainder of the respondents were educated in either
internal medicine,
medicine,

internal medicine with adolescent

family practice, or family practice with

adolescent medicine.

"The majority of those responding

practiced in a teaching hospital
private practice

(29%)"

(40%) or were in a

(Pinkston-Koenigs & Miller,

1995,

p. 348). The respondents had practiced for a mean of 13.7
years.
Of the respondents,
adolescents and 41%

87% prescribed contraceptives for

(n = 218) reported prescribing Depo-

Provera. No relationship existed between prescribing DepoProvera while in training and using Depo-Provera in
practice

(x^ = 3.0, p > .05) . Depo -Provera was more likely
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to be prescribed by obstetricians than pediatricians
.01). Those respondents

(p <

(59%) who prescribed

contraceptives other than Depo-Provera stated that they
did not include it because of lack of need in their
practice,

the absence of FDA approval, or both.

Of those physicians who prescribed Depo-Provera, 36%
required their patients to sign informed consent forms. A
written protocol for Depo-Provera use was reported by 25%.
Twenty-seven percent said that they prescribed DepoProvera to minors who were not emancipated and without
parental consent.
Pinkston-Koenigs and Miller

(1995) determined the

physicians prescribed Depo-Provera for three groups :
exclusively for mentally retarded patients

(43%), medical

conditions precluding estrogen use as well as mentally
retarded patients

(24%), and others, e.g., teen mothers,

patients with history of poor compliance with other
contraceptives.
Those providers who prescribed Depo-Provera followed
an average of seven patients, each on Depo-Provera
13.8). Of those followed,
beyond 9 months,

(SD =

85% continued Depo-Provera use

and 40% continued its use beyond 21

months. Reasons for patients' discontinuation as reported
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by their physicians were menstrual irregularity (22%),
loss to follow-up

(22%), or both (13%).

Pinkston-Koenigs and Miller

(1995) had several

unanswered questions. These questions dealt with the use
of Depo-Provera in adolescents. One of the questions was
to determine if other health care providers,

such as nurse

practitioners or physician assistants, use Depo-Provera in
ways that differ from the physicians surveyed. Determining
if physicians not involved in adolescent health care use
Depo-Provera was another question posed. Other unanswered
questions included determining if there were different
indications for Depo-Provera use in adolescents and
whether the tolerance for side effects was different in
adolescents. The researchers recommend that more research
be conducted about the use of Depo-Provera in adolescents.
Pinkston-Koenigs and Miller

(1995) concluded that

less than half of the physicians who responded to the
questionnaires used Depo-Provera as a contraceptive.
Problems related to irregular bleeding were involved with
discontinuation. Little is known about the use of and
problems with the use of Depo-Provera in adolescents.
Future investigations into short-term potential problems,
such as weight gain or mood changes and long-term
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potential problems such as osteoporosis were cited as
areas for future studies by the researchers.
In another study, Harel, Biro, Kollar, and Rauh
(1996) sought to examine the reasons for adolescents'
discontinuation of the long-acting contraceptives, DepoProvera and Norplant, and to assess their experience after
discontinuation of these methods of birth control. Both of
these methods are effective, convenient, coitusindependent, and require no daily compliance, which makes
them a desirable alternative for the prevention of teenage
pregnancy.
Harel et al.

(1996) identified a sample of 72

adolescents in a hospital-based adolescent clinic who
discontinued one of the long-acting contraceptives. Of
this sample,

66 adolescent girls agreed to participate in

the survey. Of this group of girls,
Depo-Provera

3 5 discontinued use of

(Group 1) and 31 discontinued use of Norplant

(Group 2). All participants were counseled via printed
material and verbally about contraceptive methods. Each
received detailed data on their chosen method. During use
of Depo-Provera and Norplant,

the girls were assessed

every 3 months by their health care provider and
throughout the 12 months following discontinuation. The

29

adolescents were interviewed and a complete physical exam
was performed at each follow-up visit.

If clinically

appropriate, pelvic exams were performed for cultures
(gonorrhea and chlamydia)

and papanicolaou

(pap) smears.

At each visit condom use was encouraged and condoms were
supplied.
Demographic and psychosocial data, as well as
reproductive health and menstrual history, were collected
by the health care providers. A 3 -point Likert-type scale
(very, somewhat, not) was used to report perceived
satisfaction and concerns with Depo-Provera and Norplant
use. At initiation and at follow-up visits, body mass
index (BMI) was calculated. The day of removal for
Norplant and 3 months after the last injection of DepoProvera were determined to be the dates of discontinuation
of use for each method. Irregularity of menstrual flow was
defined as a flow of greater than 7 days, with an interval
of less than 21 days or greater than 35 days, or the
presence of intermenstrual spotting. Harel et al.

(1996)

defined a break in contraceptive use as the use of no
method after discontinuation of Depo-Provera or Norplant
or adoption of the next method at least one month after
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the date of discontinuation. Approval of the study was
granted by the institutional review board of the hospital.
Chi-square analysis for categoric variables and
student's two-tailed

test for paired and unpaired data,

h

as appropriate, were used for comparisons between and
within groups. Fisher hypergeometric function also was
used as appropriate. Type I error

(«) < .05 was considered

significant. Conception rates were calculated cumulatively
at monthly intervals. For descriptive data, Harel et al.
(1996) expressed the results as the mean
Harel et al.
Depo-Provera

standard error.

±

(1996) found that at the initiation of

(Group 1) the average age of the adolescents

was 16.5 ± 0.3 years. The average age at initiation of
Norplant

(Group 2) was 15.8

±

0.3 years. Seventy percent

were African-American and the remainder were Caucasian.
Group 1 BMI was 24.2 ± 0.6, and Group 2 BMI was 24.1 ±
0.9. In Group 1, the adolescents were 4.7
postmenarchal and 3.4

±

±

0.3 years

0.3 years in Group 2 (p = .002) .

Both groups reported that they were sexually active. The
mean onset of sexual activity was 14.4

±

0.2 years in

Group 1 and 14.1 ± 0.3 years in Group 2. Both groups
reported mean lifetime sexual activity as 8 ± 1. Fortyfive percent of the adolescents who chose Norplant had
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been pregnant in the past, and 2 9% of the adolescents had
a past history of abortion. Of those who chose DepoProvera, only 23% had been pregnant in the past,

17% of

whom had a past history of abortion.
Of the adolescents who discontinued Depo-Provera, 15%
stopped after the first injection, 44% after the second
injection,

23% after the third injection, and 18% after

the fourth or more injections. Of those who discontinued
Norplant, only one was removed in the first 6 months of
use, whereas 23% of removals occurred within the first
year, 2 9% in the second year, and 48% in the third year of
use.
Harel et al.

(1996) found that half

(48% of the Depo-

Provera users and 52% of the Norplant users) were
"somewhat" satisfied with their chosen method. Complete
dissatisfaction was expressed by a substantial minority
(29% of Depo-Provera users and 35% of the Norplant users ) .
Ninety percent of the adolescents in both groups had
discussed their decision to discontinue the method with
another person,

typically their mother or boyfriend. Only

17% of the parents from both groups of adolescents were
reportedly in complete agreement with the decision to
discontinue the methods.
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Irregular bleeding, weight gain, and mood changes,
with no statistical difference between the groups, were
the most common reasons for discontinuation of either
Depo-Provera or Norplant. Three adolescents from the DepoProvera users and 5 adolescents from the Norplant users
reported desire for pregnancy as their reason for
discontinuation. Of these adolescents, two from each group
said that their partners influenced their choice because
of a desire for pregnancy.
Prior Norplant users had a reestablishment of regular
menstrual bleeding significantly earlier

(p = .01) than

those who were prior Depo-Provera users. Eighty-one
percent of those who were prior Norplant users resumed
regularity during the first month after discontinuation.
Of those who had used Depo-Provera, only 50% resumed
regularity during the first month after discontinuation.
Of those who regained menses, the total duration of
menstrual bleeding during the first month after
discontinuation was 7.0

±

2.0 days in the Depo-Provera

users and 5.0 dt 2.5 days in the Norplant use r s . Harel et
al.

(1996)

found no statistical difference in the total

days of bleeding between the groups at 2 to 5 months after
discontinuation. The probable return to ovulation was
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significantly delayed after discontinuation of DepoProvera compared with adolescents who had previously used
Norplant.
The adolescents who discontinued use of Depo-Provera
had an increase in BMI of 1.1 Æ 0.3
with initiation, paired

t.

(p = .0005)

(compared

test, p = .0005) . Those

adolescents who discontinued Norplant gained 1.3
their BMI

±

0.6 in

(compared with initiation, paired L test, p =

.03. At 6 months after discontinuation of the methods
(compared with BMI at discontinuation, paired J t test, p =
.01 in Group 1 [Depo-Provera users], and paired t test, p
= .02 in Group 2 [Norplant users]) there was a further
significant increase in BMI. Harel et al.

(1996) found no

significant changes in BMI at > 9 months after
discontinuation of either method.
Sexual activity immediately after discontinuation of
both these methods was reported by 4 6% of the adolescents
using Depo-Provera and 36% of the adolescents using
Norplant. Documentation of sexually transmitted infection
(STI) occurred in 2 0% of the adolescents using DepoProvera and in 2 0% throughout the follow-up after
discontinuation. Nine adolescents using Depo-Provera were
documented as having abnormal pap smears

(atypia and
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squamous intraepithélial lesions), and 2 were documented
after discontinuation as having abnormal pap smears. After
discontinuation of Norplant,

55% of the adolescents

reported no change in sexual interest, 26% reported less
interest,

and 19% reported greater sexual interest. More

frequent sexual intercourse was reported by 48%. After
discontinuation,

20% of the adolescents reported

consistent condom use, compared with 3% while using
Norplant. During their last sexual intercourse only 33%
reported condom use. Harel et al.

(1996)

found of the

adolescents who used Norplant, an STI was documented in
64% during Norplant use and 32% during follow-up after
discontinuation of the method. Forty-five percent of the
adolescents who used Norplant had abnormal Pap smears
(atypia and squamous intraepithélial lesions)

during use

of the method and 10% after discontinuation.
After discontinuation of Depo-Provera or Norplant,
only 62% of the adolescents using Depo-Provera and 63%
using Norplant utilized a new method with no break in
contraceptive practice. Nonpermanent,

less effective

methods, with the condom being the most popular, were used
by 3 7% of the Depo-Provera users and 23% of the Norplant
users. A highly effective method,

such as an oral
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contraceptive, was used as their next method by only 2 6%
of those who used Depo-Provera and 3 9% of those who used
Norplant. No method of contraception was adopted after
discontinuation in 26% of the adolescents in who used
D e p o -Provera and 19% of those who used Norplant.
During the follow-up after discontinuation,
adolescents from Group 1 (Depo-Provera users)

7

and 15 from

Group 2 (Norplant users) had conceived (x^ = 5.96, p =
.01) . At 12 months after discontinuation,

the cumulative

conception proportion was significantly higher

(Fisher

exact test, p = .01) among the adolescents who
discontinued Norplant. Prenatal care was initiated by the
majority of these adolescents during the first trimester.
Only 57% of the adolescents in both groups continued
to be satisfied with their decision to stop the methods.
Fifty-one percent of those who discontinued Depo-Provera
and 3 9% who discontinued Norplant said that they would
like to reinstate their former methods in the future.
Harel et al.

(1996) concluded that discontinuation of

D epo-Provera and Norplant among adolescents was largely
the result of irregular menstrual bleeding and weight
gain. Counseling about potential side effects should be
provided before initiation of these methods and throughout
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the use of these methods to help increase continuation.
Health care providers should manage excessive bleeding
episodes in an attempt to decrease discontinuation with
these methods. Another potential side effect was a delay
in the return of ovulatory regular cycles and fertility
which may persist for several months after discontinuation
with Depo-Provera. Harel et al.

(1996) recommended that

users of these methods be cautioned that the immediate
risk for pregnancy after discontinuation is high. The
health care provider should also make an effort to
increase the use of a barrier method of contraception in
adolescents.
In a similar study, Davidson et al.

(1997) conducted

a prospective study among poor and minority women designed
to investigate rates of Depo-Provera discontinuation and
subsequent rates of unprotected intercourse and unintended
pregnancy. The study sample consisted of 4 91 women who
were selected from three large hospital-based family
planning clinics serving poor and ethnically diverse
populations in New York City, Dallas, and Pittsburgh.
Eligibility criteria were assessed through a waiting room
screening form. The eligibility criteria were as follows:
at least 15 years of age, initiating Depo-Provera use, and
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having received contraceptive counseling. All women who
met the criteria were asked to participate in the study.
Interviews were conducted with more than 95% of these
women.
Davidson et al.

(1997) conducted subsequent

interviews by telephone at one year after initiation. A
sample of 4 02 women was reinterviewed for this analysis
yielding a rate of 83%. Those lost to follow-up did not
significantly differ in terms of age, parity,

income,

educational attainment, employment status, or
race/ethnicity.
Depo-Provera discontinuation rates and unintended
pregnancy rates following discontinuation were assessed by
use of life-table analyses. Comparisons between subgroup
were based on the Wilcoxon-Gehan test. Depo-Provera
discontinuation was defined as not having an injection
within 4 months of the prior injection.
Davidson et al.

(1997) assessed unintended pregnancy

rates by use of life-table analyses of the discontinuers
at risk for unintended pregnancy (defined as those having
sexual intercourse and not wanting to become pregnant at
the time of discontinuation). Unintended pregnancies were
defined as those that occurred within 9 months of
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discontinuation of Depo-Provera in women not wanting to
become pregnant.
The women were primarily from minority racial and
ethnic backgrounds
and 7% white)

(67% Hispanic, 26% African American,

and were of low socioeconomic status

(62%

had household incomes below $10,000, and 49% did not have
a high school diploma).
Thirty-one percent of the participants were
teenagers,

and the average age of the sample was 23.4

years. Sixty-seven percent of the sample reported at least
two pregnancies,
pregnancy,

65% had at least one unintended

and 53% were teenagers at the time of their

first delivery.
Davidson et al.

(1997)

found that within the first

year of Depo-Provera use, the majority of women
discontinued use. At 12 months the cumulative life-table
discontinuation rate was 58%. Fifty-one percent of those
who discontinued use of Depo-Provera

(31% of the sample)

did so after the first injection. Eighteen percent of
those who discontinued use of Depo-Provera did so after
the second injection.
Race/ethnicity and parity had significant effects on
rates of discontinuation. African Americans had lower
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rates of discontinuation than Hispanics. Those women with
two or more live births were less likely to discontinue
Depo-Provera than women with fewer than two births. Other
characteristics such as age, educational attainment,
number of unintended pregnancies,

intention to have

additional children, and partner's attitude toward DepoProvera had no significant effect on discontinuation
rates.
Those who discontinued Depo-Provera use were asked an
open-ended question about their primary reason for
discontinuation of the method. The majority attributed
discontinuation to the side effects of the method rather
than to the difficulty of returning to the clinic every 3
months. Three quarters cited either amenorrhea or
irregular bleeding or other side effects,

such as weight

gain, headaches, mood changes, or acne, as the primary
reason for discontinuation. However, only 12% cited
difficulties in returning to the clinic as reason for
discontinuation. Other reasons cited as the main reason
for discontinuation were not being sexually active
and wanting to become pregnant

(5%)

(4%).

Follow-up of Depo-Provera discontinuers was limited
to the discontinuers who were at risk for unintended
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pregnancy

(i.e., those who were sexually active and did

not want to become pregnant at the time of
discontinuation). Subjects who used not being sexually
active as the "main reason" for discontinuation and those
who had not had sexual intercourse since discontinuing
Depo-Provera were eliminated. Those discontinuers who
listed wanting to become pregnant as the main reason for
discontinuation or who listed this as a factor in their
discontinuation decision were also eliminated.
Davidson et al.

(1997)

found that half of the group

at risk for pregnancy either did not make the transition
to a new contraceptive or used a contraceptive only
occasionally. Thirty-three percent never used a
contraceptive method during sexual intercourse, 4% rarely
used birth control, and 13% reported that they sometimes
used a contraceptive. The remainder

(50%) of the at-risk

group reported always using birth control. Of those who
reported ever using a contraceptive,
used methods were oral contraceptives

the most frequently
(55%) and condoms

(31%).
Davidson et al.

(1997) found that many Depo-Provera

discontinuers soon experienced an unintended pregnancy. At
6 months post-Depo-Provera discontinuation the cumulative
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life-table pregnancy rates were 17%, and at 9 months post
discontinuation the rates were 20%. Educational
attainment,
pregnancies,

race/ethnicity, number of unintended
and intention to have additional children

were not found to have any significant effects on
pregnancy rates.
Frequency of contraceptive use and whether or not the
respondent was a teenager heavily influenced the rates of
unintended pregnancy. Those women who never, rarely, or
sometimes used contraception had cumulative 9 -month lifetable pregnancy rates six times higher than those women
who always used contraception. Furthermore,

teenagers were

at significantly greater risk for unintended pregnancy
than older women. The consequence of being a teenager and
never or only occasionally using contraception resulted in
an alarmingly high 9-month cumulative pregnancy rate of
53%.
Davidson et al.

(1997) concluded that Depo-Provera

discontinuers were at great risk for an unintended
pregnancy because they did not make the transition to
consistent use of another contraceptive. This risk was
particularly high among teenagers. The majority of women
reported that they discontinued Depo-Provera because the
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side effects were unacceptable, even after receiving
proficient and thorough counseling regarding side effects
of Depo-Provera.
Davidson et al.

(1997) recommended development of

more aggressive procedures for alerting women about
upcoming Depo-Provera appointments and for identifying and
contacting women who miss injections as one possible
solution to the high rates of discontinuation. Follow-up
also may reduce rates of unintended pregnancies among
those who discontinue Depo-Provera by reinforcing the need
for an alternative contraceptive method.
Westfall, Main, and Barnard (1996) conducted a
similar study to determine one-year continuation rates of
Depo-Provera among a cohort of women who began using the
injectable contraceptive between 1993 and 1995. Westfall
et al.

(1996) believed that the information obtained from

the study was necessary to determine the feasibility and
cost-effectiveness of Depo-Provera.
Women who received a contraceptive injection between
January 2, 1993, and March 31, 1995, were provided a
numerical identifier that allowed tracking over repeat
visits for Depo-Provera injections. Demographic variables
included age, race, payment type, and the clinic location.
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Injections were given according to the manufacturer's
recommended protocol of one injection at least every 3
months

(approximately 14 weeks or 98 days)

in every

clinic. Calculation of continuation rates was based on
return visits that occurred between 60 and 105 days from
the previous visit. Injections that occurred prior to or
up to one week following the 98^^ day after a woman's
previous injection were considered repeat injections.
After 105 days women who received repeat injections were
recorded as having discontinued use and considered to be
at risk for pregnancy and were provided with pregnancy
tests.

If these women reentered the study, the repeat

injection was recorded as an initial use.
Westfall et al.

(1996) calculated overall

continuation rates using the number of injections for
which patients were eligible, based on the length of time
they had been enrolled in the study. The number of women
eligible for their next injection who actually received it
was calculated as the intervisit continuation rate. The
12-month continuation rate was calculated as the product
of the first three intervisit continuation rates.
The study sample consisted of 5,178 women who
received Depo-Provera injections. Seventy-nine percent of
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the sample was white,
9% were black

12% were Hispanic,

(4%), Asian

(3%) , or other

and the remaining
(2%) . The

majority of the sample were between the ages of 23 and 3 0
years

(44.8%), followed by ages 19 and 22 years

(25%).

Eighty-five percent of the women listed method of payment
as self-pay, while 10% of the women in the sample were
reimbursed for services through Medicaid.
All women in the study received at least one
injection. Forty-one percent discontinued use or were lost
to follow-up after the initial injection. The second
injection was administered to 2,813 women; of this number,
35% were lost to follow-up or discontinued use. The third
injection was received by 1,662 women; of those,

32%

discontinued or were lost to follow-up. A fourth injection
was received by 995 women. The mean time between
injections was 84 days, with a standard deviation of 6.0
days

(the respective median values were 85 and 6.6 days) .
Westfall et al.

(1996) revealed a one-year

continuation rate for Depo-Provera users of 23%. Of the
women who received a first injection,

57% returned for

their next v i s i t . Between the second and third visits the
intervisit continuation rate increased to 63% and between
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the third and fourth visits the continuation rate
increased to 65%.
For visits occurring after the first year of DepoProvera use, intervisit continuation rates were somewhat
higher. During the first year of the study the mean
intervisit continuation rate among users was approximately
62%. Further,

66% of women who received a fourth injection

went on to receive a fifth, and nearly 68% of those women
obtained a sixth injection, and over 75% of this group
received their seventh Depo-Provera injection.
No statistically significant differences were found
in continuation rates based on clinic site, age,
ethnicity, or payment type. A sample of approximately 200
women who discontinued Depo-Provera use after their first
injection was followed. Difficulty tolerating side effects
was reported as the main reason for terminating use. Of
this sample,

12% were reported as lost to follow-up.

Westfall et al.

(1996) found that overall

continuation rates for Depo-Provera in the population
described here was very low. Only 57% of users returned
for their second injection, and only 23% of those eligible
for a full year of contraceptive protection completed all
four injections. Poor continuation between the first and

46

second injection was followed by slightly improved
intervisit continuation rates across successive intervals.
Westfall et al.

(1996) recommended careful

identification of those women who actually desire long
term contraception and counseling aimed at side effects as
important toward improving continuation rates. An
effective strategy to enhance continuation is reminder
postcards or telephone calls. These methods might prove
impractical among younger women who may not want parents
or partners to know of their contraceptive practices.
Enhancing access to clinics that provide Depo-Provera
might also improve continuation rates, especially among
younger w o m e n .
Sangi-Haghpeykar, Poindexter, Bateman, and Ditmore
(1996) conducted a prospective study to examine methodrelated experiences and acceptability of Depo-Provera
among women who used this method of birth control for the
first time. The specific goals of the study were as
follows : (a) to examine the longitudinal changes in
bleeding patterns and occurrence of side effects,

(b) to

determine Depo-Provera's continuation and failure rates,
and

(c) to delineate reasons for discontinuation of use.
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Sangi-Haghpeykar et al.

(1996) surveyed 536 women who

had decided to use Depo-Provera for the first time at 17
provider sites in Texas. The research protocol was
approved by the review boards for human research at all
participating institutions before data collection. Each
subject completed a baseline questionnaire after giving
informed consent. Data on the subject's source of
information about Depo-Provera, reasons for selecting this
method,

concerns about Depo-Provera, and reproductive and

contraceptive histories were collected. The project staff
collected demographic data that was available in patients'
charts.
Fifty percent of women who received the injection
were black, 25% were white,

and 25% were Hispanic. The

women who selected Depo-Provera ranged in age from 13 to
46 years. The mean length of education was 11.9

±

2.9

years. Because the majority were seen at public clinics
serving primarily low-income women, the income level of
participants was quite low. The mean annual income for the
group was $5,978.
characteristics,

In respect to reproductive
the number of pregnancies for the women

receiving the injection ranged from 0 to 10. The number of
births for subjects of this study ranged from 0 to 7. One
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quarter of the sample had never been pregnant, and one
third had experienced no births. In addition,

32.5% of the

women reported at least one elective abortion.
Sangi-Haghpeykar et al.

(1996) conducted follow-ups

with the women through three consecutive injections.
Patients were asked about their experience with DepoProvera during the past 3 months at each follow-up. They
were asked about any side effects and/or changes in
bleeding patterns, overall satisfaction with the method,
and about plans to use the method for the next 3 months.
The participant's medical records were used to verify
receipt of each injection.
Information was collected from each subject by way of
a self-administered questionnaire upon return visit to the
clinic. The questionnaires were available in English and
Spanish. Any questions the subjects had concerning the
questionnaire were responded to by a clinic nurse or staff
member.

If the subjects did not return to the clinic,

the

information was obtained by telephone or mail.
Many women were unable to be assessed for side
effects, bleeding irregularities, extent of satisfaction
with Depo-Provera,

and future contraceptive plans upon

discontinuing the use of Depo-Provera because they did not
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complete the follow-up questionnaires at their return
visit to the participating clinics and they could not be
contacted by telephone or mail. However, the medical
records of all study participants,

including women who had

not completed the follow-up questionnaires, were reviewed
for receipt of each injection to reach a more precise
estimate of Depo-Provera's continuation rate. An
individual who, based on medical records,

stopped the use

of Depo-Provera and switched to another method or to no
method was defined as a discontinuer.
Groups of interest were compared by Sangi-Haghpeykar
et al.

(1996), using analysis of variance,

student t test,

categorical procedure, and life-table analysis. The
Wilcoxon signed-rank test was utilized to measure extent
of satisfaction with Depo-Provera. Furthermore,
categorical data analysis with repeated measures was used
to examine changes in reports of side effects and abnormal
bleeding patterns over time. A p ^ .05 was considered
significant. SAS System statistical software was utilized
to perform all analyses.
The questionnaire administered 3 months after the
first Depo-Provera injection was completed by 463
participants

(86%). Of those who completed the
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questionnaire,

325

(70%) indicated plans to continue with

Depo-Provera for another 3 months ; the remainder were
opting to discontinue use of the method. The 6-month
follow-up questionnaire was completed by 285

(88%) of the

women who had chosen to continue use of Depo-Provera. Of
these women, 226

(79%) said they planned to continue use

of this method for another 3 months. Of those who
indicated plans to continue with Depo-Provera, 195

(86%)

completed the 9-month follow-up questionnaire.
Sangi-Haghpeykar et al.

(1996) estimated a method

failure rate of 0.2 per 100 using life-table analysis. The
failure rate applies to the entire first year of use,
since women who received a fourth injection at 9 months
were contacted and questioned regarding pregnancies during
the 3 months following that injection.
At each follow-up contact, weight gain was the most
commonly reported side effect,

indicated by 3 8 to 46% of

the recipients. Another common complaint reported by
nearly one fifth of the women at each follow-up contact
was headaches. No side effects associated with the use of
Dep o -Provera was reported by about one third of women
surveyed. Regarding changes in bleeding pattern,
amenorrhea was the most frequent complaint. Other commonly
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reported side effects were spotting or irregular bleeding
(40 to 46%) and longer periods

(19 to 26%). Less than 4%

reported no change in bleeding patterns while using DepoProvera.
Sangi-Haghpeykar et al.

(1996) also investigated

longitudinal changes in bleeding patterns and experience
of side effects. Weight gain, acne or skin problems, and
amenorrhea appeared to significantly increase over time

(p

< .001), but complaints of having longer periods decreased
(p < .001).
Ninety-five percent of the original cohort

(n = 53 6)

were successfully followed through medical records for the
assessment of Depo-Provera's one-year continuation rate.
Twenty-nine women were lost to follow-up.
Within one year after receiving the first injection
of Depo-Provera,

377 patients discontinued use, resulting

in a one-year continuation rate of 28.6% using life-table
analysis. The cumulative discontinuation rate after 3
months of use was 36.4%, after 6 months was 54.4%, after 9
months was 64.6%, and after 12 months was 71.4%.
Women who continued to use Depo-Provera were compared
with those who discontinued the use of this method. There
were no observed differences in age, ethnic origin.
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education, number of pregnancies or births, or plans for
having children in the future. However,

those who had used

Depo-Provera for the entire study period and those who
indicated plans to continue to use this method at the
final survey were more likely to be unmarried

(82%) than

those who opted to stop the use of this contraceptive
(66%)

(p < .05).
Method discontinuation was significantly associated

with concern about the side effects of Depo-Provera before
receiving the first injection. At 6 months of follow-up,
women who indicated plans to continue Depo-Provera use
were less likely to have concerns about the method's side
effects before the first injection than were those who
opted to discontinue after 6 months. Complaints about side
effects associated with previous methods were not related
to Depo-Provera's discontinuation.
Sangi-Haghpeykar et al.

(1996) obtained data

concerning the one-year continuation rate of Depo-Provera
through medical records and was acquired for 95% of the
study cohort. Women who stopped using Depo-Provera were
significantly less satisfied with the effect of this
contraceptive on their health and were more likely to
regret having used it than those who continued to use this
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method

(p < .001). In other measures of satisfaction,

including convenience of the method and expense, the two
groups were similar. These conclusions were consistent at
3, 6, and 9 months of follow-up.
Sangi-Haghpeykar et al,

(9196) found reports of

weight gain, headaches, and depression during the first 3
months of use were significantly more frequent among women
who stopped Depo-Provera use than among those who
continued use. In addition, reports of more frequent
periods were more common among women who discontinued
Depo-Provera use, whereas women who continued to use this
contraceptive were more likely to report less frequent
periods and lighter bleeding. After 6 months of DepoProvera use, women who ceased to use this method cited
more frequent periods and increased cramping, whereas
women who continued to use this method were more likely to
report lighter menstrual bleeding. After 9 months of use,
frequent complaints of women who ended Depo-Provera use
were weight gain, nervousness, amenorrhea, and heavier
bleeding, whereas those who continued to use this method
reported spotting or irregular bleeding.
The women who continued to use Depo-Provera at each
follow-up contact were less likely to have experienced
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side effects associated with the use of this method
compared with those who discontinued use. Women who
continued to use Depo-Provera after 3 months of use
reported an average of 1.6 side effects, compared with 2.3
for those who stopped its use at this time

(p < .001) . An

average of 1.6 side effects was reported by women
continuing to use Depo-Provera at 6 months,
2.1 by those who stopped use

compared with

(p < .05). The average number

of side effects reported by the two groups at 9 months of
use was 1.6 and 2.4, respectively (p < .05).
Sangi-Haghpeykar et al.

(1996) found that intolerable

side effects and changes in menstrual bleeding were the
most frequently reported reasons specified for
discontinuing use of Depo-Provera. Two to 6% of the women
who terminated Depo-Provera did so because they wanted a
child. Reasons for discontinuation of Depo-Provera were
examined in respect to demographic characteristics and
reproductive histories. White women and those with a
greater number of previous pregnancies were significantly
more likely to stop Depo-Provera because of side effects
than Blacks and Hispanics or women with less previous
pregnancies

(p < .05). Age, education, marital status,

change in marital status, and number of live births were
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not related to the reasons cited by women for
discontinuing the use of Depo-Provera.
Women who discontinued the use of Depo-Provera were
questioned regarding the contraceptive method they planned
to use instead of Depo-Provera. The most commonly selected
method was oral contraceptives followed by condoms. Of the
women who ended Depo-Provera use between 3 and 10% were
not planning to use a contraceptive method, and nearly one
fifth were undecided. The rest planned to use a variety of
other methods.
Sangi-Haghpeykar et al.

(1996) discovered the most

commonly reported side effects were weight gain and
headaches, and the most frequently reported changes in
bleeding pattern were amenorrhea and irregular bleeding.
Menstrual changes were reported with greater occurrence
than nonmenstrua1 side effects.
The primary reasons for switching from one method to
another, or to no method, among women at risk for
unintended pregnancies were concerns about the potential
side effects associated with the use of contraceptives and
the actual experience of side effects. Concerns about
Depo-Provera's side effects before the first injection
were associated with Depo-Provera acceptability which was
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consistent with these reports. Sangi-Haghpeykar et al.
(1996)

found that the primary reasons for method

discontinuation were the effects of this contraceptive on
health and bleeding patterns. Reasons cited for stopping
the use of Depo-Provera were weight gain, headaches,
depression, nervousness, heavier bleeding, more frequent
periods,

increased cramping, and amenorrhea, whereas those

who continued to use it reported lighter bleeding and less
frequent periods.

In studies of Depo-Provera acceptability

conducted in other countries, a change in menstrual
pattern,

in particular amenorrhea, was also the main

reason for Depo-Provera discontinuation.
Marital status also was associated with acceptability
of Depo-Provera. Of the women who continued use of DepoProvera,

a significantly higher proportion were unmarried

compared with those who stopped use of this method.
Acceptability and continued use of Depo-Provera among
unmarried women may have profound implications for the
occurrence of unintended pregnancies. Unintended
pregnancies have been reported to be highest among teens,
minorities,

and unmarried women.

Changes in bleeding patterns over time, such as
polymenorrhea and prolonged bleeding and spotting, have
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been reported to be more frequent after the first
injection and are gradually replaced by longer cycles,
less bleeding,

and total amenorrhea after repeated

injections. A significant increase in the reports of
amenorrhea among subjects who received repeated injections
was found, whereas reports of longer periods decreased
with duration of use. Women may be expected to stop use of
Depo-Provera with repeated injections because amenorrhea
is not acceptable to many users and appears to be a reason
for discontinuation. Other nonmenstrua1 complaints that
increased with continued use were weight gain and acne or
skin problems. Another cause of Depo-Provera
discontinuation in the present investigation was weight
gain.
Sangi-Haghpeykar et al.

(1996) observed the one-year

continuation rate of Depo-Provera to be 28.6%. This is
considerably lower than Depo-Provera continuation rates
reported in other countries. Reasons specified by patients
for stopping the use of Depo-Provera suggest that certain
aspects of this injectable contraceptive appear to be
intolerable and lead to discontinuation. Careful patient
education and counseling of women unwilling to tolerate
side effects,

such as menstrual changes, headaches, or
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weight increases,

can minimize the use of Depo-Provera in

inappropriate candidates. A detailed description of all
the side effects that are likely to occur should be
included in information about Depo-Provera. This
information may help women select a contraceptive that is
appropriate for their needs and concerns,

leading to less

contraceptive switching, which has been reported to
increase the risk of unintended pregnancies.

Summary
Depo-Provera was found to be a very popular
contraceptive choice for adolescent females,

especially

among those who have used other types of contraception or
who have been pregnant. Although Depo-Provera is safe,
effective,

and obtainable for adolescents, once adolescent

females are started on Depo-Provera, they often fail to
return for subsequent injections.
Freda et al.

(1996) found that the most common reason

reported for choosing Depo-Provera was forgetting to take
the oral contraceptive pills ; however, dissatisfaction
with oral contraceptives was the typical reason given.
Other reasons for choosing Depo-Provera were dislike of
oral contraceptive pills and ease and perceived safety of
Depo-Provera.
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Common side effects experienced by Depo-Provera users
included irregular periods, heavy bleeding, amenorrhea,
headaches,

and hair loss. Discontinuation of Depo-Provera

among adolescents appears to be the result of intolerable
side effects such as irregular menstrual bleeding and
weight gain.
Possible methods to increase compliance with DepoProvera include careful patient education and counseling
about potential side effects. These adolescents should
also be counseled on the need to use condoms because DepoProvera does not protect against sexually transmitted
diseases. Enhancing access to clinics that provide DepoProvera may also lead to improved continuation rates.
Reminder postcards and telephone calls would also be
beneficial in improving continuation rates as well as
identifying those adolescents who are discontinuing DepoProvera.
When discontinuation with Depo-Provera has been
confirmed,

the adolescent is at risk for unintended

pregnancy. Every effort should be made to have the
adolescent make the transition to another method of
contraception in an attempt to prevent pregnancy.

Chapter III
The Method

The purpose of this descriptive study was to
determine the factors which influence the choice and
discontinuation of Depo-Provera among adolescents. This
chapter will describe the research methods used to
investigate the variables under study. The design,
population,

sample, and setting as well as instrumentation

and methods of data collection also will be described in
this chapter.

Design of the Study
A descriptive design was utilized to determine the
factors which influence the choice of Depo-Provera and
discontinuation of Depo-Provera as a contraceptive method
identified by adolescents. A descriptive design is
utilized to observe, describe, and document aspects of a
situation as it naturally occurs with no manipulation of
variables

(Polit & Hungler,

1995). Therefore,

60

a
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descriptive design was appropriate for this study as there
was no manipulation of variables.
The variables of interest were the factors which
influence adolescents'

choice of Depo-Provera as a

contraceptive method and the factors which influence
adolescents' discontinuation of Depo-Provera as a
contraceptive method as measured by the McCarter DepoProvera Questionnaire.
The control variables were the gender and age of the
participants and method of contraception utilized by the
participants. Subjects were adolescent females between the
ages of 13 and 2 0 years who were currently using or had
used Depo-Provera as a contraceptive.
The extraneous variables included the truthfulness of
the subjects in completing the questionnaire and were the
following: the subject's age; race ; previous pregnancies,
if any; number of living children,

if any; other methods

of birth control used; reasons for choosing Depo-Provera;
length of time Depo-Provera had been used; reasons for
discontinuing Depo-Provera, if no longer using it;
satisfaction with Depo-Provera; and whether consideration
would ever be given to using Depo-Provera in the future,
if no longer using Depo-Provera.
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Research Questions
The research questions in this study were as follows:
1. What are the factors that influence the choice of
Depo-Provera as a contraceptive method by adolescents?
2. What are the factors that influence
discontinuation of Depo-Provera as a contraceptive method
by adolescents?

Limitations
The following limitations were identified for this
study:
1. The small sample size of this study made the
results or not generalizable.
2. The use of only two clinics in a southeastern
state made the results ungeneralizable.
3. The population studied included only adolescent
females between the ages of 13 and 2 0 years.

Setting,

Population,

and Sample

The setting for this study was a city in the
Southeast with a population of 33,000 in the city and
64,000 in the surrounding county. The setting was a
private pediatric clinic and a State Department of Health
clinic.
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The population studied was adolescent females who
were currently using or who had once used Depo-Provera as
a method of contraception. The convenience sample
consisted of 100 adolescent females between the ages of 13
and 2 0 years who were currently using or who had once used
Depo-Provera as a method of contraception and were willing
to participate in the study. If the adolescent was 18
years of age or younger, parental consent was obtained for
participation in the study.

Methods of Data Collection
This section describes the methods of data
collection. A description of instrumentation, procedure,
and data collection are included.
Inst rument at io n . The McCarter Depo-Provera
Questionnaire which was used in this study was an 11-item,
researcher-developed questionnaire

(see Appendix A ) . The

McCarter Depo-Provera Questionnaire elicits demographic
data,

such as age, race, number of pregnancies, number of

living children,

and other methods of birth control

utilized by the subject. Other information obtained on the
McCarter Depo-Provera Questionnaire included reasons for
choosing Depo-Provera, reasons for discontinuing DepoProvera,

if no longer using this method, and satisfaction
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with Depo-Provera. Also included was an optional question
to assess three things the subject liked most and three
things the subject liked least about Depo-Provera. Because
this tool was developed by the researcher,

there is no

established validity or reliability. Content validity was
established by a panel of experts who reviewed and
evaluated the t o o l .
Procedures. Following approval by the Committee on
the Use of Human Subjects in Experimentation at
Mississippi University for Women (see Appendix B ) , each
proposed site was contacted by letter

(see Appendix C) for

permission to distribute questionnaires to clientele who
were currently or had ever utilized Depo-Provera as a
contraceptive.

Packets which included a description of the

purpose of the study and the participant's written consent
(see Appendix D ) , a written consent for a parent or legal
guardian of subjects younger than 18 years of age
Appendix E ) , a copy of the questionnaire,

(see

along with

instructions for its completion, and a self-addressed,
stamped envelope were delivered to each site for mailing
to each potential subject. To assure anonymity,

the

subject was instructed not to write her name on the
questionnaire or on the return envelope. The self
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addressed,
researcher,

stamped envelope was addressed to the
the only person who saw the questionnaire. A

follow-up postcard was mailed to those who had not
responded within 10 working days after the initial mailing
(see Appendix F ) .

Method of Data Analysis
Descriptive statistics were utilized to describe and
summarize data obtained with respect to demographic
variables,

adolescents' reasons for choosing Depo-Provera,

their reasons for discontinuing Depo-Provera,

and their

satisfaction with Depo-Provera. Data from each question on
the McCarter Depo-Provera Questionnaire was analyzed using
frequency distributions and percentages.

Chapter IV
The Findings

The purpose of this study was to determine the
factors which influence the utilization and
discontinuation of Depo-Provera among adolescents. A
survey design was implemented for this descriptive study.
A questionnaire was utilized to obtain information from
adolescent females about their reason for choosing DepoProvera, and, if no longer using Depo-Provera, their
reasons for discontinuing use. Data from each
questionnaire were analyzed using frequency distributions
and percentages. The findings from the study are presented
in this chapter.

Description of Sample
The sample consisted of adolescent females who
responded to the questionnaire. A total of 100
questionnaires was mailed to female adolescents ranging in
age from 13 years to 20 years who reside in Mississippi.
Only 14 subjects returned the questionnaire, despite being
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sent a reminder postcard. The composition of the sample by
age consisted of no 13-year-olds
(0%) , two 15-year-olds
17-year-old
olds

(0%) , no 14-year-olds

(14%) , two 16-year-olds

(7%), four 18-year-olds

(14%), and three 20-year-olds

(29%), two 19-year(22%). Eleven subjects

(79%) were African American, and 3 subjects
Caucasian. Nearly half

(14%) , one

(22%) were

(43%) of the subjects had

previously been pregnant. Of the subjects who had been
pregnant,

4 subjects had been pregnant one time, one

subject had been pregnant three times, and one subject did
not specify the number of previous pregnancies. Of those
subjects who had been pregnant, 4 had one living child,
one had 3 living children, and one had no living children.
Demographic characteristics of the subjects are presented
in Table 1.
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Table 1
D emographic Characteristics of the Sample

Characteristic

n

%

0
0
2
2
1
4
2
3

0 .0
0 .0
14 .0
14 .0
7.0
29.0
14 .0
22 .0

3
11

21.0
79. 0

Previous pregnancy
Yes
No

6
8

43 .0
57 .0

No. of previous pregnancies
0
1
3
Not reported

8
4
1
1

57.0
29.0
7.0
7 .0

Age

(years)
13
14
15
16
17
18
19
20

Race
Caucasian
African American

N o t e . N = 14.

Contraceptive history. Eleven of the subjects

(79%)

had used some form of birth control method in the p a s t . Of
the 11 subjects who had utilized a birth control method,

3

had used the pill, 3 had used condoms, 4 had used the pill
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and condoms, and one had used Norplant. Those subjects who
reported previous pregnancies had utilized the following
methods: the pill
pill and condoms

(n = 1), condoms

(n =2), and both the

(n = 3). Three subjects

(21%) did not

report using any previous contraceptive methods.
Reasons for choosing Depo-Provera. Thirteen of the
subjects said they chose Depo-Provera because they only
had to remember it every 3 months. Three subjects chose
Depo-Provera because they felt that it was very effective.
Four subjects chose Depo-Provera because it was
inexpensive or free. Four subjects selected Depo-Provera
because no one could tell they were using the method.
Three subjects selected other reasons for choosing DepoProvera and specified,

"Don't have to remember to take it

everyday," "thought I would have lessmenstruation,"

and

"sometimes my periods don't come."
Use of Depo-Provera. The majority of the subjects had
used Depo-Provera for 12 months

(36%). Two of the subjects

(14%) had used Depo-Provera for 36 months. The remaining
subjects reported the following time lengths of DepoProvera use : 3 months, 4 months,
months,

10 months, and 13 months.

6months,

8 months, 9
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Two subjects reported that they no longer use DepoProvera, Reasons for discontinuation cited by both
subjects were physical symptoms and menstrual problems.
Physical symptoms included nausea, dizziness, weight gain,
headaches, hair loss, fatigue, breast tenderness,

acne,

skin problems, or facial hair. Menstrual problems included
vaginal discharge,

irregular periods,

spotting between

periods, or no period.
Half of the subjects

(50%) stated being very

satisfied with Depo-Provera. Six subjects

(43%) were

somewhat satisfied with Depo-Provera. Only one subject
reported being very dissatisfied with Depo-Provera.
Thirteen subjects

(93%) said that they would consider

using Depo-Provera in the future. One subject

(7%) stated

that she would not consider using Depo-Provera in the
future.
The last question on the questionnaire was an
optional question which asked the subject to list three
things that she liked most about Depo-Provera and three
things which she liked least about Depo-Provera. Three
common responses to what was liked most about Depo-Provera
were "only have to take it every three months"

(n = 5),

"no periods"

(n = 3).

(n= 4), and "it's very effective"
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Other responses about what was liked best about DepoProvera were as follows:
"No one can tell that I'm using it."
"No cramps."
"Gain weight."
"Don't get sick."
The most commonly cited responses to what the
subjects like least about Depo-Provera were "spotting"
= 4) and "periods too long"

(n

(n = 4). The following

responses were reported by three subjects:

"eat a lot,"

"gain weight," and "headaches." Responses made by 2
subjects were "hate needles" and "dizziness." One subject
responded with a complaint of a "stiff arm."

Most of the adolescents who responded to the
questionnaire were over the age of 18 years. Eleven of the
subjects were African Americans, and almost half of the
subjects had been pregnant at least one time. Of those who
had been pregnant,

the majority had been pregnant one time

and had one living child. Only one subject who had been
pregnant reported having no living child. Half of the
subjects reported previously using oral contraceptive
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pills,

condoms, or both. Three subjects had never used any

birth control method before beginning Depo-Provera.
Over three quarters of the sample chose Depo-Provera
because it was required only every 3 months. Other common
reasons reported for choosing Depo-Provera were because
the medication was effective,

inexpensive or free, and

inconspicuous. Depo-Provera had been in use by the
subjects from 3 months to 3 years. The majority of the
subjects had used Depo-Provera for 12 months.
Only 2 subjects were no longer using Depo-Provera.
Both of the subjects who no longer used Depo-Provera
reported that they discontinued use of the method because
of physical and menstrual symptoms. Only one subject was
very dissatisfied with Depo-Provera; the remaining
subjects were very satisfied or somewhat satisfied. Only
one subject said that she would never consider using DepoProvera in the future.
Responses about three things liked most and three
things liked least about Depo-Provera yielded many
differing responses. The most common responses to what was
liked most about Depo-Provera were "only have to take it
every three months,"

"no periods," and "it's very

effective." The most common responses to what was liked
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least about Depo-Provera were "spotting,"
long,"

"periods too

"eat a lot," "gain weight," and "headaches."

We, as family nurse practitioners, may be the first
contact many young adolescent females make to aid them
with their initial family planning assessment. By becoming
familiar with their perceptions about Depo-Provera, we can
educate them about the good points of using Depo-Provera
as well as teach them about the possible side effects
experienced with Depo-Provera. By being diligent in our
teaching about possible side effects and utilizing methods
to reduce side effects, we, as nurse practitioners, may be
able to increase the number of adolescents who choose
Depo-Provera and also increase compliance with this highly
effective contraceptive method.

Chapter V
The Outcomes

Adolescent pregnancy and birth rates in the United
States are the highest of any developing country (Spitz et
al.,

1996). Although there are many contraceptive options

available to adolescents, unplanned pregnancies among
adolescents continue to occur. The purpose of this study
was to observe, describe, and document the factors which
influence the choice of and discontinuation of DepoProvera as a contraceptive method as identified by
adolescents. Becker's Health Belief Model served as the
theoretical framework for this descriptive study. The
research questions for this study were as follows : What
are the factors which influence the choice of Depo-Provera
as a contraceptive method as identified by adolescents and
what are the factors which influence the discontinuation
of Depo-Provera as a contraceptive method as identified by
adolescents?
The convenience sample consisted of 14 adolescent
females who received health care at a local state health
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department and at a local pediatric clinic in Northeast
Mississippi. The instrument utilized for the collection of
data was the McCarter Depo-Provera Questionnaire.
Descriptive statistics were generated to describe the
factors which influence adolescents'

choice of and

discontinuation of Depo-Provera as a contraceptive.
Responses to the instrument were analyzed using frequency
distributions and percentages.
A summary and discussion of the findings of this
study are presented in this chapter. The conclusions,
implications for nursing, and recommendations which
emerged from these findings also are discussed.

Summary of.. Finding s
Demographics of-the sample. The sample for this study
consisted of 14 adolescent females between the ages of 15
years and 2 0 years who responded to the McCarter DepoProvera Questionnaire. The majority of the sample
were African American. Eleven of the subjects

(79%)

(79%) had

used some form of birth control method in the p a s t . Six
subjects had been pregnant and of those five reported
having living children. Those subjects who reported
previous pregnancies had used the pill and/or condoms.
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Only 3 subjects reported never having used any method of
contraceptive before beginning Depo-Provera.
Use of Depo-Provera. Most of the subjects

(86%)

reported choosing Depo-Provera because they only had to
remember it every 3 months. Over half of the sample

(57%)

had used Depo-Provera for 12 months or longer. Of those
who discontinued use of Depo-Provera, physical and
menstrual symptoms were the causes for discontinuation.
Ninety-three percent of the subjects were satisfied with
Depo-Provera and stated that they would use the method in
the future.

Discussion
The findings of this study indicated that the
majority of the adolescents

(93%) were satisfied with

Depo-Provera. Most of the subjects

(86%) chose Depo-

Provera because they only had to remember to get an
injection every 3 months. Only 3 subjects had never used
contraception before beginning Depo-Provera. Those who had
utilized another method of birth control had used oral
contraceptive pills, condoms, or both. Almost half of the
subjects
(n = 2)

(43%) had previously been pregnant. The subjects
who had discontinued use of Depo-Provera

attributed discontinuation to physical and menstrual

77

symptoms. Only one subject stated that she would never
consider using Depo-Provera in the future.
In a similar study, Freda et al.

(1996) found that

dissatisfaction with oral contraceptives was the typical
reason given for choosing Depo-Provera. Seventy-eight
percent of the women interviewed expressed satisfaction
with the method, and 64% planned to continue use of DepoProvera. The most common reason provided for termination
of Depo-Provera was a scheduled tubal ligation. Sixty-five
respondents experienced side effects. The most commonly
reported side effects included amenorrhea, headaches, hair
loss, irregular periods, and heavy bleeding. The
respondents did not perceive the side effects serious
enough to prevent use of Depo-Provera. In the present
study,

7 subjects had previously used the pill, and all

but one subject chose Depo-Provera because they only had
to remember it every 3 months. Those subjects who
discontinued Depo-Provera attributed discontinuation to
physical and menstrual problems. Ninety-three percent of
the subjects were satisfied with Depo-Provera and would
consider using the method in the future.
Westfall et al.

(1996) found that the one-year

continuation rate for Depo-Provera among women who

78

participated in their study was only 23%. Of the women who
received a first injection, only 57% returned for their
next visit. The intervisit continuation rate increased to
63% between the second and third visits. The continuation
rate increased to 65% between the third and fourth visits.
These researchers found no statistically significant
difference in continuation rates based on clinical site,
age, ethnicity, or payment type. The main reason reported
for terminating use of Depo-Provera was difficulty
tolerating side effects. Because the majority of the
subjects in the present study had used Depo-Provera for 12
months or longer,

it is possible that discontinuation

rates were not as high in this study as in the study
conducted by Westfall et al. because their study began
when the women were receiving their first injection.
Westfall et al.

(1996) did see an increase in continuation

rates with each injection.
In another comparable study, Davidson et al.

(1997)

found that within the first year of use, the majority of
the women in their study discontinued use of Depo-Provera.
More than half of the women discontinued use after the
first injection. Discontinuation was attributed by a
majority of the women to side effects,

such as amenorrhea.
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irregular bleeding, weight gain, headaches, mood changes,
or acne. Thirty-one percent of the subjects were teenagers
and were found to be at significantly greater risk for
unintended pregnancy after discontinuation of DepoProvera. The 9 -month cumulative pregnancy rate of these
teenagers who never or only occasionally used
contraception after discontinuation of Depo-Provera was
53%. This study, unlike the present study, followed women
during their first year of use of Depo-Provera. Because
the present study consisted largely of a sample of
adolescents who had been on Depo-Provera for 12 months or
longer, the continuation rates may have been higher due to
the number of previous injections received by the
adolescents.
The Health Belief Model provided the theoretical
framework for this study. This theory uses
sociopsychological variables in the explanation of
preventive health behavior. The Health Belief Model has
been shown by current research to be a value expectancy
approach to explaining and predicting health behaviors
that go beyond straight information giving. This approach
can be used to intervene in encouraging contraceptive use
among adolescents. Because contraceptive action involves a
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preventive health decision followed by correct and
consistent use, the model may have useful applications to
both the prevention and compliance aspects of
contraceptive behavior

(Zellman, 1984). Individual

perceptions of adolescents related to their perceived
susceptibility to pregnancy are important. Modifying
factors include the adolescents' knowledge about pregnancy
prevention,

the types of contraceptives,

the availability

of contraceptives, and the consequences of pregnancy. The
likelihood of action includes the adolescents' perceived
benefits of a long-acting contraception as well as
perceived side effects of use with this type of
contraceptive.

Limitations
The limitations of this study were internal as well
as external. A lack of randomization was the greatest
threat to generalization of this study's findings. Sample
selection was restricted to the number of subjects who
responded to the questionnaire. The sampling design was
one of convenience from only two clinics ; therefore,

a

true representation of adolescents who use Depo-Provera
must be questioned. The subjects were required to have
parental consent to participate in the study if they were
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age 18 years or younger, even though parental consent was
not needed for them to receive the Depo-Provera injection.
This researcher believes that the need for parental
consent for participation in the study had a negative
effect on participation in the study. The instrument was
researcher-designed and had only face validity.

Conclusions
The following conclusions were derived from the
findings of this study :
1. The majority of the adolescents had used another
method of birth control before using Depo-Provera.
2. Almost half of the adolescents had been pregnant
before using Depo-Provera.
3. The adolescents chose Depo-Provera because they
only had to remember it every 3 months.
4. Most of the adolescents had used Depo-Provera for
12 months or longer.
5. Generally adolescents are satisfied with DepoProvera.
6. The majority of the subjects in this study would
use Depo-Provera in the future.
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Implications for Nursing
Adolescent pregnancy is a national dilemma that
transcends the boundaries of socioeconomic class, race,
and ethnicity. Adolescent pregnancy has negative
consequences for both mother and child ("Teen Pregnancy,"
1997) . Nearly 60% of all pregnancies in the United States
are unintended, and almost one half of these occurred
because contraception failed or was not used properly
(Marble,

1996). Adolescent girls who become pregnant are

more likely to be poor and have limited future
possibilities. Pregnant teens also are less likely to seek
prenatal care and more likely to have medical problems
during their pregnancy

("Teen Pregnancy," 1997) .

This study identified some of the characteristics of
adolescent girls who chose Depo-Provera. In this study,
the adolescents were half as likely to have previously
used another method of birth control and have experienced
a pregnancy. These adolescents chose Depo-Provera because
of the convenience of receiving an injection only once
every 3 months, because this method is inconspicuous to
others, because of the effectiveness of the method, and
because the injection was inexpensive or free. Only 2 of
the adolescents in this study had experienced side effects
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which they perceived severe enough to discontinue DepoProvera, All but one of the subjects were satisfied with
Depo-Provera and would consider using Depo-Provera in the
future.
This study sought to improve the knowledge base of
nurse practitioners as to the factors that influence
adolescents'

choice of Depo-Provera for contraception as

well as the factors that influence their discontinuation
of Depo-Provera. By understanding the factors that
influence adolescents to choose Depo-Provera, nurse
practitioners can speak to potential users about the
benefits. Conversely, by being familiar with factors that
lead to discontinuation of Depo-Provera, nurse
practitioners can counsel adolescents about these factors
in an attempt to increase compliance with this very
effective method of contraception. By encouraging
adolescents to choose Depo-Provera and counseling them on
the possible side effects, compliance may be increased
which could in turn lead to a decrease in adolescent
pregnancy.

Recommendations for Further Study
Based on the findings of this study, the following
recommendations are made for future research in nursing:
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1. Replication of the study with a larger, more
diverse sample.
2. Replication of the study without parental consent
for participation in the study if not required for
administration of Depo-Provera.
3. Conduction of research to include past sexual
history and educational level.
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McCarter Depo-Provera Questionnaire

1.

2.

How old are you?
13 years
14 years
15 years
16 years
What

17
18
19
____ 2 0

years
years
years
years

is your race?
Caucasian
African-American
Native Indian
Asian
Spanish
Other

3.

Have you ever been pregnant?
Yes (if yes, how many times?)_______
No

4.

How many living children do you have?_____

5.

What other methods of birth control have you used?
(Please check all that apply)
The pill
Condom
Spermicidal foam or cream
Condom with spermicidal foam or cream
Norplant
- lUD
Other method (please specify)_________________
Why did you choose Depo-Provera? (Please check all
that apply)
Only have to remember it every 3 months
Very effective
Inexpensive or free
No one can tell I'm using it
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7.

How long have you used Depo-Provera?__________________

8.

If you no longer use Depo-Provera, why did you stop
using Depo-Provera? (Please check all that apply)
Physical symptoms (nausea, dizziness, weight
gain, headaches, hair loss, fatigue, breast
tenderness, acne or other skin problems, or
facial hair)
Menstrual problems (vaginal discharge, irregular
periods, spotting between periods, or no
periods)
Mental problems (nervousness, anxiety, or
depression)
Other (please specify)____________________________

9. How satisfied were you with Depo-Provera?
Very satisfied
Somewhat satisfied
Neither satisfied nor dissatisfied
Somewhat dissatisfied
Very dissatisfied
10.

Would you ever consider using Depo-Provera in the
future?
Yes
No

11.

Please list 3 things you like most and 3 things you
like least about Depo-Provera. (Optional)
Like most
a. _________________________
b. _________________________
c. _________________________

Like least
a. _____________________
b. _____________________
c. _____________________
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(601)329-7142
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April 8, 1998

Ms. Carey E. McCarter
c/o Graduate Program in Nursing
Campus
Dear Ms. McCarter:
I am pleased to inform you that the members of the Committee
on H uman Subjects in Experimentation have approved your proposed
research as submitted provided any participant under the age of 18
has consent from a parent or guardian.
The Committee does not fee
that age 16 is a proper age.
I wish you much success in your research.
Sincerely,

Susan Kupis6h, Ph.D.
Vice President
for Academic Affairs
SK :wr
cc:

Mr. Jim Davidson
Dr. Mary Pat Curtis
Dr. Bonnie Lockard
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A g e n c y Consent F o r m

12 9 Point Harbor Drive
West Point, MS 39773

April 20, 1998

To:

(Clinic)

Dear __________
I am a graduate student at Mississippi University for Women in
Columbus, Mississippi, pursuing a Master of Science in Nursing with a
specialty as a Family Nurse Practitioner. My anticipated date of
graduation is August 1998.
As a requirement for graduation, I am conducting a research study to
determine the factors which influence adolescents' choice of and
discontinuation with Depo-Provera as a contraceptive.
I would like to
distribute the McCarter Depo-Provera Questionnaire topatients atyour
clinic who are currently using or who have used Depo-Provera as a
means of contraception. Attached for your review is a
copy ofthe
McCarter Depo-Provera Questionnaire, the subject's Consent to
Participate, and a Parental or Guardian Consent, if required. The
questionnaire takes approximately 1 to 2 minutes to complete. All data
obtained from the questionnaire will be kept strictly confidential.
I would very much appreciate your consideration of this matter. You
can reach me at (601) 494-7720 or (601) 244-1190 if you have any
questions regarding this study. I will be happy to answer any
questions over the telephone or arrange a personal meeting to discuss
any issues that you might have.
Please sign below if you grant permission for distribution of the
McCarter Depo-Provera Questionnaire to patients of your clinic. A
return envelope is enclosed for your convenience.

Representative of Clinic
Sincerely,

Carey E. McCarter

Date
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Carey E. M cCarter, RN
129 Point H arbor Drive
West Point, Mississippi 39773
Aptil 29, 1998
Dr. Pimla Su11i\an, RN. C'S, D SN
Children’s Health Center
3491 Bhiecutt Road
Columbus. Mississippi 39701
Dear Dr. Sullivan:
I am a graduate student at Mississippi University for Women in Columbus, Mississippi
pursuing a Master o f Science in Nursing with a specialty as a Family Nurse Practitioner. My
anticipated date o f graduation is August 1998.
As a requirement for graduation, I am conducting a research stud) to determine the factors
which influence adolescents’ choice o f and discontinuation with Depo-Provera as a
corttracepth e. I would like to distribute, by means o f U.S. Mail, the M cCarter DepoProvera Questionnaire to patients o f your clinic who are currenti) using or who have utilized
Depo-Provera as means o f contraception. Attached for ) our review is a copy o f the
M cCarter Depo-Provera Questionnaire, the subject's Consent to Participate, and a parental
or guardian consent, if required. I he questionnaire takes approxitnatel) I to 2 minutes to
complete. All data obtained from the questionnaire will be kept strictly confidential.
I would vety m uch appreciate your consideration o f this matter. You can reach me at 601494-7720 or 601-244-1190 if you have an) questions regarding this study. I will be happy
to answer any questions over the telephone or arrange a personal meeting to discuss any
issues that you might have.
Please sign below if you grant permission for distribution of the M cCarter Depo-Provera
Questionnaire to patients o f your clinic. A return envelope is enclosed for your convenience.

^ep/esentative 6 f Children's Health Center

Sincerel).

C’aiev F. McCarter

Date
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Carey E. M cCaiter
129 Point I larbor Drive
West Point, Mississippi 39773
April 29, 1998
Office o f Public Health Nursing
Mississippi State Department o f Health
P O Box 1700
Jackson, M S 39215
Dear Sir:
I am a graduate studetit at Mississippi Universit)' for Women in Columbus, Mississippi
pursuing a M aster o f Science in Nursing with a specialty as a Family Nurse Practitioner.
M y anticipated date o f graduation is August 1998.
/\s a requirement for graduation, I am conducting a research study to determine the factors
which influence adolescents’ choice o f and discontinuation with Depo-Provera as a
contraceptive. I would like fo distribute by means o f U.S. Mail, the M cCarter DepoProvera Questionnaire to patients at the l owndes Count) Health Departm ent in Coulmbus
who are current!)- using or who have utilized Depo-Provera as means o f contraception.
Included for your review are a copy o f materials submitted for approval by the Committee
on the Use o f Hum an Subjects in Experimentation at Mississippi Universitv for Women, a
copy o f the M cCarter Depo-Provera Questionnaire, a copy o f the subject’s Consent to
Participate, and a copy o f the Parental or Guardian Consent Form. The questionnaire
takes approximately 1 to 2 minutes to complete. All data obtained from the questionnaire
will be kept strictly confidential.
I would very much appreciate your consideration o f this matter. Please call me at 601-4947720 if you hav e any questions regarding tliis study. 1 will be happy to answer any
questions over the telephone or arrange a personal meeting to discuss any issues that you
miglit have.
Please sign below if you grant permission for distribution o f the M cCarter Depo-Provera
Questionnaire at your clinic. A return envelope is enclosed for your convenience.

Representative o f l.owndes Onunty Health Dept.

Carey E. M cCarter, RN

. Date
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Partic i p a n t Consent F o r m

If you are 18 years old or younger and have never been
pregnant, parental or guardian consent is required for
participation in this study.

Dear Participant,
My name is Carey McCarter. I am a registered nurse currently
enrolled at Mississippi University for Women. As part of the
requirements for graduation from the Master of Science in
Nursing program, I am conducting a research study. The purpose
of the study is to determine the factors which influence choice
of and discontinuation with Depo-Provera among adolescents.
This information will be helpful in discovering ways in which
any adverse side effects may be reduced or eliminated. All
information reflected on the questionnaire will be
confidential. I am the only person who will see the
questionnaire, and it will be destroyed after analysis of data.
To assure your anonymity, please do not write your name on the
questionnaire or the return envelope.
Participation in this study is on a voluntary basis, and your
participation in this study will not affect your health care
services. If you are between the ages of 13 and 18 years and
have never been pregnant, parental or guardian consent is
required for participation in this study. Please have your
parent or legal guardian sign the enclosed consent form. By
signing below, you are agreeing to participate in this study.
Please return the questionnaire, the Participant Consent Form,
and the Parental or Guardian Consent Form (if required) in the
enclosed self-addressed, stamped envelope provided. Thank you
for your time and effort in participating in this study.
Signature of Participant

Date

Signature of Researcher

Date
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Parental or G u a r d i a n C o nsent F o r m

Dear Parent or Guardian,
My name is Carey McCarter. I am a registered nurse
currently enrolled at Mississippi University for Women. As
part of the requirements for graduation from the Master of
Science in Nursing program, I am conducting a research
study. The purpose of the study is to determine the
factors which influence adolescents' choice of and
discontinuation with Depo-Provera as a contraceptive. This
information will be helpful in discovering ways in which
any adverse side effects may be reduced or eliminated. I
am requesting your permission to allow your child or ward
to take part in this study by filling out the enclosed
questionnaire. All information reflected on the
questionnaire will be confidential. I am the only person
who will see the questionnaire, and it will be destroyed
after analysis of the data.
Participation in this study is on a voluntary basis, and
participation in this study will not affect your child's
health care services. By signing below, you are agreeing
to allow your child or ward to participate in this study.
Please return this consent form along with the
questionnaire and the participant consent form in the
self-addressed, stamped envelope provided. Thank you for
your time and effort in participating in this study.

Signature of Parent or Guardian

Date

S i g n a t u r e of R e s e a r c h e r

Date
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Follow-Up Card

June 2, 1998
Dear Participant,
My name is Carey McCarter. I am a registered nurse currently
enrolled at Mississippi University for Women. As part of the
requirements for graduation from the Master of Science in Nursing
program, I am conducting a research study. On May 2 0*"^ I sent to
you a packet which contained information about the study as well
as consent forms, the questionnaire, and a return envelope. All
information reflected on the questionnaire will be confidential.
I am the only person who will see the questionnaire, and it will
be destroyed after analysis of the data.
Participation in this study is on a voluntary basis. Please
return the questionnaire, the Participant Consent Form, and the
Parental or Guardian Consent Form (if required) in the selfaddressed, stamped envelope provided. Your time and effort in
participating in this study are greatly appreciated.
Sincerely,
Carey McCarter

